FIELD: pharmaceutics.
SUBSTANCE: invention relates to novel compounds of formula I and pharmaceutically acceptable salts thereof, in which values for groups R1, R2, R3, R4 and X are defined in patent claim. Invention also relates to pharmaceutical compositions, having activity of inhibitor of Fms-like tyrosine 3 (FLT3) containing said compounds and pharmaceutically acceptable salts thereof.
EFFECT: invention relates to use of said compounds and pharmaceutical compositions for treating, controlling or relieving symptoms of AML (acute myeloid leukaemia).
35 cl, 93 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHODS AND INTERMEDIATE COMPOUNDS FOR PREPARING IMATINIB, OPTIONALLY RADIOLABELLED | 2006 |
|
RU2440999C2 |
IMIDAZOPYRIDAZINES | 2012 |
|
RU2662443C2 |
BICYCLIC AMINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | 2007 |
|
RU2465275C2 |
PYRAZOLO[1,5-a]PYRIMIDINE AND THIENO[3,2-b]PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK-4 | 2011 |
|
RU2604062C2 |
NEW DERIVATIVES OF HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD FOR MODULATION OF AUTOIMMUNE DISEASES, METHOD FOR PREPARING THESE COMPOUNDS | 2000 |
|
RU2255937C2 |
BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2589878C2 |
IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | 2009 |
|
RU2518089C2 |
PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | 2006 |
|
RU2407739C2 |
PYRIMIDINE DERIVATIVES WITH ACTIVITY TOWARDS MCH | 2005 |
|
RU2373197C2 |
AMINOPYRAZINE DERIVATIVES AND MEDICATIONS | 2010 |
|
RU2535217C2 |
Authors
Dates
2016-10-20—Published
2012-03-14—Filed